Elinzanetant

Elizanetant (NT-814) is an orally active, selective NK-1,3 receptor antagonist. Elizanetant can reduce the levels of estradiol and progesterone, and is used in the study of vascular motor symptoms and sleep disorders related to menopause in women[1][2][3].

Product Specifications

CAS Number

[929046-33-3]

Product Name Alternative

NT-814; BAY3427080

UNSPSC

12352005

Hazard Statement

H302

Target

Neurokinin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/elinzanetant.html

Purity

99.82

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)(C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C(N(C2=CN=C(N3[C@@H](CN4[C@@](COCC4)([H])C3)CO)C=C2C5=C(C=C(C=C5)F)C)C)=O

Molecular Formula

C33H35F7N4O3

Molecular Weight

668.64

Precautions

H302

References & Citations

[1]Alvaro, Giuseppe; Andreotti, Daniele; Belvedere, Sandro; Di Fabio, Romano; Falchi, Alessandro; Giovannini, Riccardo.Pyridine derivatives as NK receptor inhibitors and their preparation, pharmaceutical compositions, and use in the treatment of psychotic disorders.CN101305011B|[2]Simon JA, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1) . Menopause. 2023 Mar 1;30 (3) :239-246.|[3]Steve Pawsey, et al. Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women. J Clin Endocrinol Metab. 2021 Jul 13;106 (8) :e3221-e3234.